Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

High Hydroxyurea Usage in Sickle Cell Anemia Regardless of Patient Demographic

Vivian Phan, Ju Ae Park, Robin Yates Dulman, Angela Lewis, Noravy Briere, Bailey Notarangelo, Elizabeth Yang

Blood (2023) 142 (Supplement 1): 1142.

https://doi.org/10.1182/blood-2023-175017

Published: 2023

Journal Articles

Gut Microbiota Diversity and Composition Are Altered during Therapy in Pediatric Acute Lymphoblastic Leukemia Patients

Elizabeth Yang, Svetlana Rassulova, Dhwani Sahjwani, An Harmanli, Ryan Fassnacht, Lopa Mehta, Melissa Agnello, Pamela Camejo, Suchitra Hourigan

Blood (2021) 138 (Supplement 1): 3364.

https://doi.org/10.1182/blood-2021-149174

Published: 2021

Journal Articles

Clostridioides Difficile Carriage Rate Increases during Pediatric ALL Treatment

Elizabeth Yang, Svetlana Rassulova, Dhwani Sahjwani, An Harmanli, Ryan Fassnacht, Lopa Mehta, Melissa Agnello, Pamela Camejo, Suchitra Hourigan

Blood (2021) 138 (Supplement 1): 1211.

https://doi.org/10.1182/blood-2021-151596

Published: 2021

Journal Articles

The Effect of Voxelotor on Exercise Capacity of Youths with Sickle Cell Anemia

Vivian Phan, Laura Caldarera, Ana Lucia Cortez, Kari Wheeler, Sandra K. Larkin, Sangah Nancy Park, Robin Yates Dulman, Noravy Briere, Angela Lewis, Frans A. Kuypers, Jared Hershenson, Elizabeth Yang

Blood (2021) 138 (Supplement 1): 2045.

https://doi.org/10.1182/blood-2021-149163

Published: 2021

Journal Articles

The Effect of Patient Navigators on Health-Related Quality of Life in Sickle Cell Anemia: The SHIP-HU Study

Wally R Smith, MD, Donna k McClish, PhD, Shirley Johnson, BA, LSW, Richard Lottenberg, MD, India Sisler, MD, Daniel Sop, BS,MS, Anthony Villella, MD, Darla K Liles, MD, Elizabeth Yang, MD PhD, Ian Chen, MD

Blood (2019) 134 (Supplement_1): 2168.

https://doi.org/10.1182/blood-2019-131266

Published: 2019

Journal Articles

The Effect of Patient Navigators on Laboratory Parameters of Hydroxyurea Adherence in Sickle Cell Anemia: The SHIP-HU Study

Wally R Smith, MD, Donna k McClish, PhD, Richard Lottenberg, MD, India Sisler, MD, Daniel Sop, BS,MS, Shirley Johnson, BA, LSW, Anthony Villella, MD, Darla K Liles, MD, Elizabeth Yang, MD PhD, Ian Chen, MD

Blood (2019) 134 (Supplement_1): 2309.

https://doi.org/10.1182/blood-2019-131201

Published: 2019

Journal Articles

The Association of Painful Crises with Patient Reported Outcomes in Sickle Cell Disease: The SHIP-HU Study

Donna k McClish, PhD, Wally R. Smith, MD, Victoria Okhomiuna, MS, PhD, Daniel Sop Mouaffo, BS, MS, Richard Lottenberg, MD, Ian Chen, MD, India Sisler, MD, Shirley Johnson, BA, LSW, Darla K Liles, MD, Elizabeth Yang, MD PhD, Thokozeni Lipato, MD

Blood (2018) 132 (Supplement 1): 3509.

https://doi.org/10.1182/blood-2018-99-114869

Published: 2018

Journal Articles

Gut Microbiome in Survivors of Childhood Acute Lymphoblastic Leukemia

Ronay Thomas, B.S., Wendy Shukwan Wong, PhD, NIccole Piguet, MD MPH, Jennifer Dean, MD, Alissa Mills, John Deeken, MD, John Niederhuber, MD, Suchitra Hourigan, MD, Elizabeth Yang, MD PhD

Blood (2018) 132 (Supplement 1): 1384.

https://doi.org/10.1182/blood-2018-99-110342

Published: 2018

Journal Articles

Outcome of Initiating Hydroxyurea in Infancy for Patients with Sickle Cell Disease 2011-2018

Ronay Thomas, B.S., Robin Yates Dulman, MD, Angela Lewis, MSN, FNP-BC, CPHON, Bailey Notarangelo, BS, RN, Elizabeth Yang, MD PhD

Blood (2018) 132 (Supplement 1): 4816.

https://doi.org/10.1182/blood-2018-99-114174

Published: 2018

Journal Articles

A Ser725Arg mutation in Band 3 abolishes transport function and leads to anemia and renal tubular acidosis

Elizabeth Yang, Patricia Seo-Mayer, Kimberly Lezon-Geyda, Katherine E. Badior, Jing Li, Joseph R. Casey, Reinhart A. F. Reithmeier, Patrick G. Gallagher

Blood (2018) 131 (15): 1759–1763.

https://doi.org/10.1182/blood-2018-01-827725

Published: 2018

Journal Articles

Comparison of Clinical Outcomes Between Adult and Pediatric Patients (pts) with Sickle Cell Disease (SCD): 3-Year (y) Follow-up in a Prospective, Longitudinal, Noninterventional Registry Trial

Matthew M. Heeney, MD FRCP(C), Brad Baltz, MD, Patricia Adams-Graves, MD, Elizabeth Yang, MD PhD, Carole Paley, MD, Jason Esposito, MSHS, Katie McNamara, MSHS, CCRA, Elliott Vichinsky, MD, Alex George, MD, PhD

Blood (2014) 124 (21): 4890.

https://doi.org/10.1182/blood.V124.21.4890.4890

Published: 2014

Journal Articles

Clinical Outcomes For Patients With Sickle Cell Disease: 24-Month Follow-Up In An Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

Matthew M Heeney, MD, Brigitta U. Mueller, MD, Brad Baltz, MD, Patricia Adams-Graves, MD, Elizabeth Yang, MD, PhD, Carole Paley, MD, Jason Esposito MSHS, McNamara Katie MSHS CCRA, Elliott Vichinsky, MD

Blood (2013) 122 (21): 988.

https://doi.org/10.1182/blood.V122.21.988.988

Published: 2013

Journal Articles

12-Month Follow-up for Patients with Sickle Cell Disease in an Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

Matthew M. Heeney, MD, Brigitta U. Mueller, MD, Brad Baltz, MD, Patricia Adams-Graves, MD, Elizabeth Yang, MD, PhD, Carole Paley, MD, Jason Esposito, MSHS, Elliott P. Vichinsky, MD

Blood (2012) 120 (21): 1010.

https://doi.org/10.1182/blood.V120.21.1010.1010

Published: 2012

Journal Articles

Targeting Busulfan to Concentration Steady State of 600–700 ng/Ml Is Associated with Robust Engraftment and Decreased Toxicity in Patients with Sickle Cell Disease Receiving An HLA Identical Donor Transplant

Jennifer Domm, MD, Elizabeth Yang, MD, PhD, Richard Ho, MD, Adetola a Kassim, MD, Haydar Frangoul, MD

Blood (2011) 118 (21): 1966.

https://doi.org/10.1182/blood.V118.21.1966.1966

Published: 2011

Journal Articles

p19Arf Cooperates with Shp2 in Lymphoid Leukemogenesis

Xiaolan Chen, MD, PhD, Yuhui Huang, Ph.D., Ling Yan, Ph.D., Marie Brault, Zhizhang Wang, Maryann T Arildsen, Ph.D., Elizabeth Yang, MD, PhD

Blood (2008) 112 (11): 3809.

https://doi.org/10.1182/blood.V112.11.3809.3809

Published: 2008

Journal Articles

p19 Arf Cooperation in Shp2-Induced Leukemogenesis.

Xiaolan Chen, MD, PhD, Yuhui Huang, PhD, Ling Yan, PhD, Zhizhang Wang, Marie Brault, Maryann Thompson, MD, PhD, Elizabeth Yang, MD, PhD

Blood (2007) 110 (11): 1619.

https://doi.org/10.1182/blood.V110.11.1619.1619

Published: 2007

Journal Articles

Protein phosphatase 2A activates the proapoptotic function of BAD in interleukin- 3–dependent lymphoid cells by a mechanism requiring 14-3-3 dissociation

Chi-Wu Chiang, Gregory Harris, Cindy Ellig, Shane C. Masters, Romesh Subramanian, Shirish Shenolikar, Brian E. Wadzinski, Elizabeth Yang

Blood (2001) 97 (5): 1289–1297.

https://doi.org/10.1182/blood.V97.5.1289

Published: 2001

NARROW

High Hydroxyurea Usage in Sickle Cell Anemia Regardless of Patient Demographic

Gut Microbiota Diversity and Composition Are Altered during Therapy in Pediatric Acute Lymphoblastic Leukemia Patients

Clostridioides Difficile Carriage Rate Increases during Pediatric ALL Treatment

The Effect of Voxelotor on Exercise Capacity of Youths with Sickle Cell Anemia

The Effect of Patient Navigators on Health-Related Quality of Life in Sickle Cell Anemia: The SHIP-HU Study

The Effect of Patient Navigators on Laboratory Parameters of Hydroxyurea Adherence in Sickle Cell Anemia: The SHIP-HU Study

The Association of Painful Crises with Patient Reported Outcomes in Sickle Cell Disease: The SHIP-HU Study

Gut Microbiome in Survivors of Childhood Acute Lymphoblastic Leukemia

Outcome of Initiating Hydroxyurea in Infancy for Patients with Sickle Cell Disease 2011-2018

A Ser725Arg mutation in Band 3 abolishes transport function and leads to anemia and renal tubular acidosis

Comparison of Clinical Outcomes Between Adult and Pediatric Patients (pts) with Sickle Cell Disease (SCD): 3-Year (y) Follow-up in a Prospective, Longitudinal, Noninterventional Registry Trial

Clinical Outcomes For Patients With Sickle Cell Disease: 24-Month Follow-Up In An Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

12-Month Follow-up for Patients with Sickle Cell Disease in an Ongoing 3-Year, Prospective, Non-Interventional Registry Trial

Targeting Busulfan to Concentration Steady State of 600–700 ng/Ml Is Associated with Robust Engraftment and Decreased Toxicity in Patients with Sickle Cell Disease Receiving An HLA Identical Donor Transplant

p19Arf Cooperates with Shp2 in Lymphoid Leukemogenesis

p19 Arf Cooperation in Shp2-Induced Leukemogenesis.

Protein phosphatase 2A activates the proapoptotic function of BAD in interleukin- 3–dependent lymphoid cells by a mechanism requiring 14-3-3 dissociation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only